VISCOFAN FIBERCOLL-FLEX
LIVE

Serial Number

79353016

Owner

VISCOFAN, S.A.

Attorney

Douglas A. Miro

Filing Date

Jul 28, 2022

Add to watchlist:

No watchlists yet
View on USPTO

VISCOFAN FIBERCOLL-FLEX Trademark

Serial Number: 79353016 • Registration: 7497685

VISCOFAN FIBERCOLL-FLEX is a trademark filed by VISCOFAN, S.A. on July 28, 2022. The trademark is classified under Class 1 (Chemicals), Class 2 (Paints), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

VISCOFAN, S.A. (39 trademarks)

ITURRAMA, 23-31007
PAMPLONA , ES

Entity Type: 09

Trademark Details

Filing Date

July 28, 2022

Registration Date

September 10, 2024

Published for Opposition

June 25, 2024

Goods & Services

Hydrogels for medical, veterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growth, cell growth and transplantation, assays based on cells, cancer cell research, regenerative medicine, stem cell growth and drug delivery for medical use; hydrogels for cell culture for medical, veterinary and pharmaceutical purposes; hydrogels for cell growth for medical, veterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cells, namely, cell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medical, veterinary and pharmaceutical use; cells or tissues in hydrogels for medical, veterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, epithelial, muscular, and nervous tissues and organs, for medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineering, namely, hard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bones, blood and tissues for medical purposes; pharmaceutical products for the regeneration of tissues, for the repair of tissues, for the treatment of tissues, whether human or animal, namely, 3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bones, cartilages, blood vessels, nerve cell degeneration, tendon and ligament degeneration, retinal degeneration, kidney degeneration; soft tissue degenerations, for diseases with abnormal cell growth, namely, formulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy products, namely, genetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes

Inks of biological origin for printers; inks of biological origin for 3D printers

Biological materials or preparations for 3D printers, namely, bioinks, bioprinting kits comprised of collagen, biological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical use, namely, cell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medical, veterinary or pharmaceutical use; cells or tissues in hydrogels other than for medical, veterinary or pharmaceutical use; biologically compatible polymers, specifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medical, scientific and non-scientific purposes, namely, tissue implants, organoids, tissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell culture, other than for medical and veterinary purposes; engineered living tissues and tissue arrays, namely, human and animal organs, connective tissue, epithelial tissue, muscular tissue and nervous tissue, and tissue arrays, for use in scientific and medical research; biologically compatible materials, specifically, hydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 14, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 20, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 19, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 10, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Jul 1, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 25, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 25, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 11, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 11, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 5, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 17, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
May 9, 2024 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 8, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 20, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 20, 2024 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 1, 2024 NREP
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 29, 2023 GNFN
FINAL REFUSAL E-MAILED
Nov 29, 2023 GNFR
FINAL REFUSAL WRITTEN
Nov 29, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2023 TROA
REFUSAL PROCESSED BY IB
May 17, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 22, 2023 RFCS
REFUSAL PROCESSED BY MPU
Apr 22, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 1, 2023 RFCR
NON-FINAL ACTION WRITTEN
Feb 28, 2023 CNRT
ASSIGNED TO EXAMINER
Feb 23, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 25, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 21, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 20, 2022 REPR